{"database": "lobbying", "table": "lobbying_activities", "rows": [[1630071, "cca30f28-2661-4fac-8737-fd9a745cfed9", "Q4", "SLC HEALTH STRATEGIES, LLC", 401018877, "EISAI INC.", 2014, "fourth_quarter", "PHA", "Obesity product matters as well as FDA funding \nHR 4299 --Improving Regulatory Transparency for New Medical Therapies Act re: DEA scheduling of controlled substances\nS. 2862 - Transparency, Patient Access, and Effective Drug Enforcement Act of 2014 re: DEA scheduling of controlled substances", "HOUSE OF REPRESENTATIVES,SENATE", 40500, null, 0, 0, "2015-01-19T15:22:19.437000-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1630071"], "units": {}, "query_ms": 41.367625002749264, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}